在慢性缺血性左心室动脉瘤患者的不良结果中,基于CMR的风险分层
Kairui Bo1, Hui Wang1, Feifei Zhang2
1Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China (K.B., H.W., S.S., Y.G., Z.Z., S.L., L.X.).
Academic radiology
|June 19, 2025
概括
在慢性缺血性左室动脉瘤 (LVA) 中预测主要不良心血管事件 (MACE) 是至关重要的. 将临床数据与心脏磁共振 (CMR) 影像,特别是左心房应变 (LA-εa) 结合起来,可以改善风险预测.
科学领域:
- 心脏病学 心脏病学
- 医疗成像医学成像
- 预测分析是一种预测分析.
背景情况:
- 慢性缺血性左心室动脉瘤 (LVA) 的预后不佳.
- 缺乏有效的临床工具来分层MACE在LVA患者的风险.
- 心脏磁共振 (CMR) 成像为风险评估提供了潜力.
研究的目的:
- 在慢性缺血性LVA患者中确定主要不良心血管事件 (MACE) 的独立风险因素.
- 开发一个整合临床和CMR特征的预测模型.
- 评估左心房应变 (LA-εa) 在风险预测中的附加值.
主要方法:
- 从1825名心肌梗塞患者的队列中,对243名慢性缺血性LVA患者进行了回顾性分析.
- 单变量和多变量考克斯回归,包括LASSO,以确定MACE预测因子.
- 构建一个包含显著临床和CMR变量的预测名录.
主要成果:
- 82名 (33.7%) 患者在中位数为2.6年的随访期间经历了MACE.
- 独立预测因素包括年龄,NYHA类,LVA直径,LGE程度和LA-εa.
- LA-εa显著改善了模型的歧视和重新分类 (p<0.001).
结论:
- 一个整合临床数据和CMR生物标志物的预测模型有效地识别了LVA中的MACE风险.
- 左心房应变 (LA-εa) 是不良结果的重要独立预测因素.
- 该模型增强了慢性缺血性LVA患者的风险分层.
相关概念视频
01:26Aneurysm III: Interprofessional Care
30
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
30
01:25Aortic Regurgitation III: Medical Management
53
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
53
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
44
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
44
01:25Mitral Regurgitation III: Medical Management
35
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
35
01:23Mitral Regurgitation II: Clinical Features and Diagnostic Tests
60
Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
60
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
129
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
129